Bacteriophages in autoimmune disease and other inflammatory conditions

Medical Hypotheses

Volumn 62, Issue 4, 2004, Pages 493-498

  Riley, Peter A ^a  

^a ST GEORGE S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; ANTIGEN; SUPERANTIGEN;

ANTIGEN ANTIBODY COMPLEX; AUTOIMMUNE DISEASE; BACTERIOPHAGE; BACTERIUM; DISEASE COURSE; EPIDEMIOLOGY; HUMAN; IMMUNOGENICITY; INFECTION; INFLAMMATION; PRIORITY JOURNAL; REVIEW; VIRUS;

UNIDENTIFIED BACTERIOPHAGE;

EID: 1842505523     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2003.12.016     Document Type: Article

References (35)

1. Campieri M, Gionchetti P. Bacteria as the cause of ulcerative colitis. Gut 2001;48:132-5.
2. Hendrickson BA, Gokhale R, Cho JH. Clinical aspects and pathophysiology of inflammatory bowel disease. Clin Microbiol Rev 2002;15:79-94.
3. Podolsky OK. Inflammatory bowel disease. N Eng J Med 2002;347:417-29.
4. Taurog JD, Richmanson JA, Croft JT, Simmons WA, Zhou M, Fernandez-Sueiro JL, et al. The germfree state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats. J Exp Med 1994;180:2359-64.
5. Rath HC, Schultz M, Freitag R, et al. Different subsets of enteric bacteria induce and perpetuate experimental colitis in rats and mice. Infect Immun 2001;69:2277-85.
6. Duchmann R, Kaiser I, Hermann E, Mayet W, Ewe K, Meyer zum Buschenfelde KH. Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease (IBD). Clin Exp Immunol 1995;102:448-55.
7. Cooke EM. Properties of strains of Escherichia coli isolated from the faeces of patients with ulcerative colitis, patients with diarrhoea and normal persons. J Pathol Bacteriol 1968;95:101-13.
8. Burke FA, Axon ATR. Ulcerative colitis and Escherichia coli with adhesive properties. J Clin Pathol 1988;40:782-6.
9. Rembacken BJ, Snelling AM, Hawkey PM, Chalmers DM, Axon ATR. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet 1999;354:635-9.
10. Gionchetti P, Rizzello F, Venturi A, et al. Oral bacterio-therapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology 2000;119:305-9.
11. Kingsley G. Microbial DNA in the synovium - a role in aetiology or a mere bystander. Lancet 1997;349:782-6.
12. Toivanen P, Hansen DS, Mestre F, et al. Somatic serogroups, capsular types, and species of faecal Klebsiella in patients with ankylosing spondylitis. J Clin Microbiol 1999;37: 2808-12.
13. James DG. Etiology of sarcoidosis. Sarcoidosis 1994; 11(Suppl 1):43-51.
14. Ishige I, Usui Y, Takemura T, Eishi Y. Quantitative PCR of mycobacterial and propionibacterial DNA in lymph nodes of japanese patients with sarcoidosis. Lancet 1999;354: 120-3.
15. Wolfson C, Talbot P. Bacterial infection as a cause of multiple sclerosis. Lancet 2002;360:352.
16. Murray J. Infection as a cause of multiple sclerosis. BMJ 2002;325:1128.
17. Boman J, Hammerschlag MR. Chlamydia pneumoniae and atherosclerosis: critical assessment of diagnostic methods and relevance to treatment studies. Clin Microbiol Rev 2002;15:1-20.
18. Friedman SM, Posnett DN, Tumang JR, Cole BC, Crow MK. A potential role for microbial superantigens in the pathogenesis of systemic autoimmune disease. Arthritis Rheum 1991;34:468-80.
19. Yanagawa H, Nakamura Y, Yashiro M, et al. A nationwide incidence survey of Kawasaki disease in 1985-1986 in Japan. J Infect Dis 1988;158:1296-301.
20. Kato H, Fujimoto T, Inoue O, et al. Variant strain of Propionibacterium acnes: a clue to the aetiology of Kawasaki disease. Lancet 1983;ii:1383-8.
21. Levin M, Tizard EJ, Dillon MJ. Kawasaki disease; recent advances. Arch Dis Child 1991;66:1369-72.
22. Mims C, Nash A, Stephen J. In: Mims' pathogenesis of infectious disease. 5th ed. London: Academic Press; 2001. p. 47.
23. Hinton M, Hampson DJ, Hampson E, Linton AH. A comparison of the ecology of Escrierichia coli in the intestine of healthy unweaned pigs and pigs after weaning. J Appl Bacteriol 1985;58:471-7.
24. Pyun KH, Ochs HD, Wedgwood RJ, Yang XQ, Heller SR, Reimer CB. Human antibody responses to bacteriophage phi X 174: sequential induction of IgM and IgG subclass antibody. Clin Immunol Immunopathol 1989;51:252-63.
25. Bennet PM, Howe TGB. Bacterial and bacteriophage genetics. In: Balows A, Duerden BI, editors. Topley and Wilson's microbiology and microbial infections, vol 2. Systematic bacteriology. 9th ed. London: Arnold. 1998, p. 231-294.
26. Blackwell AL. Vaginal bacterial phaginosis? Sex Transm Inf 1999;75:352-3.
27. Tao L, Pavlova SI, Mou SM. Factors affecting phage induction in vaginal lactobacilli. In: Abstracts from the annual meeting of the international infectious disease society for obstetrics and gynecology USA, Las Vegas, Nevada, 25-26 April, 1997. Infect Dis Obstet Gynecol 1997;5:66.
28. Karunakaran KP, Blanchard JF, Raudonikiene A, Shen C, Murdin AD, Brunham RC. Molecular detection and seroepidemiology of the Chlamydia pneumoniae bacteriophage (ΦCpn1). J Clin Microbiol 2002;40:4010-4.
29. Hu H, Pierce GN, Zhong G. The atherogenic effects of chlamydia are dependent on serum cholesterol and specific to Chlamydia pneumoniae. J Clin Invest 1999;103:747-53.
30. -/- mouse model within six months. Mol Cell Biochem 2000;215:123-8.
31. Moazed TC, Campbell LA, Rosenfeld ME, Grayston JT, Kuo CC. Chlamydia pneumoniae infection accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice. J Infect Dis 1999;180:238-41.
32. Aalto-Setala K, Laitinen K, Erkkila L, et al. Chlamydia pneumoniae does not increase atherosclerosis in the aortic root of apolipoprotein E-deficient mice. Arterioscl Throm Vas 2001;21:578-84.
33. Caligiuri G, Rottenberg M, Nicoletti A, Wigzell H, Hansson GK. Chlamydia pneumoniae infection in mice does not induce or modify atherosclerosis in mice. Circulation 2001;103:2834-8.
34. Rubin DT, Hanauer SB. Smoking and inflammatory bowel disease. Eur J Gastroen Hepat 2000;12:855-62.
35. Wang H, Yu M, Ochani M, et al. Nicotinic acetylcholine receptor alpha7 subunit is an essential regulator of inflammation. Nature 2003;421:384-8.